$5.45
1.36% today
NYSE, May 21, 06:22 pm CET
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Amylyx Pharmaceuticals Target price 2025 - Analyst rating & recommendation

Amylyx Pharmaceuticals Classifications & Recommendation:

Buy
83%
Hold
17%

Amylyx Pharmaceuticals Price Target

Target Price $10.80
Price $5.52
Potential
Number of Estimates 5
5 Analysts have issued a price target Amylyx Pharmaceuticals 2026 . The average Amylyx Pharmaceuticals target price is $10.80. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 5 Analysts recommend Amylyx Pharmaceuticals to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Amylyx Pharmaceuticals stock has an average upside potential 2026 of . Most analysts recommend the Amylyx Pharmaceuticals stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -4.43 -1.68
732.86% 62.08%
P/E negative

2 Analysts have issued a Amylyx Pharmaceuticals forecast for earnings per share. The average Amylyx Pharmaceuticals EPS is

$-1.68
Unlock
. This is
45.81% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.59 63.78%
Unlock
, the lowest is
$-1.77 59.68%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.43 732.86%
2025
$-1.68 62.08%
Unlock
2026
$-0.97 42.26%
Unlock
2027
$-1.04 7.22%
Unlock
2028
$-0.80 23.08%
Unlock
2029
$-0.13 83.75%
Unlock

P/E ratio

Current -1.78 4.09%
2025
-3.29 84.83%
Unlock
2026
-5.69 72.95%
Unlock
2027
-5.31 6.68%
Unlock
2028
-6.90 29.94%
Unlock
2029
-42.46 515.36%
Unlock

Current Amylyx Pharmaceuticals Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Mizuho
Locked
Locked
Locked May 14 2025
HC Wainwright & Co.
Locked
Locked
Locked May 09 2025
Leerink Partners
Locked
Locked
Locked May 07 2025
Mizuho
Locked
Locked
Locked Apr 07 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 05 2025
HC Wainwright & Co.
Locked
Locked
Locked Dec 05 2024
Baird
Locked
Locked
Locked Nov 18 2024
Analyst Rating Date
Locked
Mizuho:
Locked
Locked
May 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
May 09 2025
Locked
Leerink Partners:
Locked
Locked
May 07 2025
Locked
Mizuho:
Locked
Locked
Apr 07 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 05 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 05 2024
Locked
Baird:
Locked
Locked
Nov 18 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today